erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.

150 mg/day
erlotinib: Arm A: 150 mg/day Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.

Arm A: 150 mg/Day

Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to generate skin rash.
Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.

Arm B: Cycle 1 - 150-200 mg/Day Depending on Body Weight

Total

Sex: Female, Male

no progression of disease at 12 weeks from starting treatment

150 mg/day cycles 1 - 3
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.

Erlotinib: Arm A: 150 mg/Day Cycles 1 - 3.

Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to generate skin rash.
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.

Arm B: Cycle 1 - 175 or 200 mg/Day Depending on Body Weight; C

Disease Control Rate at 12 Weeks

erlotinib 150 mg/day cycles 1 - 3
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.

A Erlotinib 150 mg/Day Cycles 1 - 3

erlotinib Cycle 1 dose modified according to patient's weight; Cycles 2 and up, dose titrated to skin rash.
erlotinib: Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.

B Erlotinib Cycle 1 Dose Modified According to Weight

Time to Progression

1-year Survival Rate

Arm A: Erlotinib 150 mg/Day

Arm B: Erlotinib 150 to 200 mg/Day Depending on Body Weight; C

Overall Study

Miguel Villalona

Arm A: 150 mg/Day Cycles 1 - 3

Carcinoma, Non-Small-Cell Lung

Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.

erlotinib

Ohio State University

OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer

A Phase II Randomized Study of OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer (NSCLC)

Ohio State University Comprehensive Cancer Center

Genentech, Inc.

Consecutive patients with first-time diagnosis of metastatic breast cancer undergoing chemotherapy with anthracyclines and/or trastuzumab.

Breast Cancer

Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up

Cardio-vascular MRI

University of Calgary, Dept. of Cardiac Sciences and Tom Baker Cancer Centre

Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)

Characterization of the Cardiotoxic Effects of Chemotherapies With Anthracyclines and Trastuzumab for Breast Cancer by Contrast-enhanced Cardiovascular Magnetic Resonance Imaging (CMR).

Oliver Strohm

adunct Research Associate Professor

University of Calgary

Group under the treatment ( sorafenib ) Maximum dose of 400 mg BID If subjects devolves adverse events, dose can be reduced.

Hepatocellular Carcinoma

Liver lesion biopsy (HCC) and blood samples will be taken from the subjects before starting the treatment course, and another biopsy and blood samples when they devolve a resistance.

Sorafenib

King Saud University Medical City

Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma

Samples will be sequenced using second generation sequencing comparison between, before and after therapy signature will be identified.

african/tyrosine

OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer

Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)

Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma

Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi